Effects of Cannabidiol on Marijuana-seeking in Humans

Participants will be asked to participate in a total of three choice sessions over two weeks
with each session day separated by at least two days. Each session day will last
approximately 8 hours.

During each study session participants will be asked to smoke a cigarette. Participants will
be asked to smoke from a marijuana cigarette. These cigarettes may contain cannabidiol or
they may not (placebo).

Participants will be asked to answer questions about how the drugs make them feel. Vitals
signs (blood pressure, heart rate, and oxygen saturation) will be measured using a
non-invasive (external) vitals monitor.

Six samples will be taken in each of the three sessions. Blood samples will be obtained via
butterfly catheter placed in a vein.

Participants will be asked to remain in the laboratory until all marijuana-related subjective
and physiological effects have returned to the original levels recorded this morning before
they smoked the first marijuana cigarette.

Inclusion Criteria:

1. Participants will be males and females aged 21-45 yrs.

2. Must be in generally good health.

3. Volunteers may meet DSM-5 criteria for current Cannabis Use Disorder but not currently
be in treatment or seeking treatment for their substance use problems.

4. An observed, temperature-tested urine specimen must test positive for THC so that
inclusion is not solely based on self-report.

Exclusion Criteria:

1. Psychiatric illness other than Cannabis or Nicotine Use Disorder. Also exclusionary is
a history or suspicion of psychosis or indication of behavior not conducive to
compliance with the study protocol.

2. Neurologic disease: structural brain abnormalities (e.g., neoplasms), cerebrovascular
disease, seizures, infectious disease, history of other neurological diseases, or head
trauma resulting in unconsciousness.

3. Cardiovascular disease: edema, chest pain or palpitations on exertion or drug use,
myocardial infarction, systolic blood pressure greater than 160 or less than 95 mmHg,
or diastolic pressure greater than 95 mmHg.

4. Pulmonary disease: obstructive pulmonary disease, apnea, cor pulmonale, tuberculosis,
dyspnea, orthopnea, or tachypnea (> 24 breaths per minute). Current diagnosis of or
treatment for asthma. History of asthma may be allowed, per the study physician's
discretion.

5. Systemic disease: e.g., endocrinopathies, renal or hepatic failure, active hepatitis
(liver function tests > 3x normal cutoff), myxedema, hypothyroidism, adrenocortical
insufficiency, Cushing syndrome, chronic GI disease, AIDS or any other autoimmune
disease involving the CNS.

6. Current substance use disorders other than Cannabis or Nicotine Use Disorder.

7. Cognitively impairment as indicated by an estimated IQ of lower than 85. Individuals
unable to give voluntary informed consent will not be enrolled. They can be neither
intoxicated nor undergoing withdrawal at the time of screening and consent.

8. Recent experimental participation (within past month).

9. Pregnancy or lactation. Females who are heterosexually active and not using
(self-report) medically approved birth control measures (e.g., sterilization, tubal
ligation, birth control pills, abstinence, intrauterine device, barrier method,
cervical cap combined with a spermicide) are not eligible. Women who are breastfeeding
will be excluded.

10. Individuals currently in, intending to seek, or court mandated for substance abuse
treatment will be excluded. Finally, participants may be withdrawn from study if they
do not comply with the study protocol, test positive for drugs of abuse other than
marijuana on the routine urine screen or decide not to participate in the study.